Pharmaceutical News

RSS

Drug coverage issues, dual eligibles program draw Democrats' interest

According to these stories from Politico and Politico Pro, some House Democrats are calling on the Department Of Health and Human Services to use the Medicare prescription drug program as a model for the health law's essential health benefits drug coverage requirement.

18 Jul 2012

Advocates, policy experts respond to FDA approval of Truvada for HIV prevention

Though the FDA's Monday approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at risk of contracting the virus "was hailed by many as an important step in the fight against AIDS, concerns that people will incorrectly use the drug -- potentially spurring drug resistance -- led others to blast the agency for not laying down tougher rules," the Wall Street Journal's "Health Blog" writes.

18 Jul 2012

FDA approves Truvada as HIV prevention strategy for high-risk, uninfected individuals

The FDA on Monday announced the approval of the first drug for pre-exposure prophylaxis (PrEP) to prevent HIV among people at risk of contracting the virus, "which some are calling a landmark in the fight against AIDS," ABC News reports.

18 Jul 2012

Vivus receives FDA approval for Qsymia to manage chronic weight

The U.S. Food and Drug Administration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management.

18 Jul 2012

Normalizing weight helps girls with eating disorders improve essential fatty acid status

A study of teenage girls with eating disorders has shown that reduced essential fatty acid levels returned to normal once the girls increased their weight to a healthy level.

18 Jul 2012

Marijuana use prior to pregnancy can increase risk of preterm birth

A large international study led by University of Adelaide researchers has found that women who use marijuana can more than double the risk of giving birth to a baby prematurely.

18 Jul 2012

Dr. Reddy's launches generic LIPITOR tablets in the U.S.

Dr. Reddy's Laboratories announced today that it has launched ATORVASTATIN CALCIUM TABLETS 10 mg, 20 mg, 40 mg and 80 mg, a bioequivalent generic version of LIPITOR (atorvastatin calcium) tablets, in the US market on July 17, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for atorvastatin calcium tablets.

18 Jul 2012

Combination of Dox with MCP shows promise against prostate cancer

Doxorubicin (Dox) is an effective anti-cancer drug, but it's also a very toxic one, causing severe heart and immune damage. The doses needed to impact tumors are not well tolerated by patients, however, researchers may have found an answer through combination therapy.

18 Jul 2012

BJP publishes data from ESTEVE's E-52862 preclinical studies on pain

ESTEVE announces the recent publication in the British Journal of Pharmacology of important preclinical data that furthers understanding of its highly potent and selective, once-daily, S1R antagonist E-52862, developed by the ESTEVE Research and Development (R&D) team.

18 Jul 2012

Emmaus receives EC Orphan Medicinal Product designation for Levoglutamide

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company's investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease.

18 Jul 2012

NIH-funded Harvard study: 6 million women in America suffer from vulvodynia

According to an NIH-funded Harvard study, an estimated six million women in America suffer from vulvodynia. Despite the astonishingly high number of those affected, the pain is often left misdiagnosed or untreated.

18 Jul 2012

Combination of tPA and 3K3A-APC may effectively treat stroke

A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally approved clot-busting therapy.

18 Jul 2012

Ferring Pharmaceuticals receives FDA approval for new colon-cleansing drug

On July 16, the U.S. Food and Drug Administration approved Prepopik (sodium picosulfate, magnesium oxide and citric acid) to help cleanse the colon in adults preparing for colonoscopy.

17 Jul 2012

Healthier levels of vitamin C can reduce inflammatory conditions

The recommended dietary allowance, or RDA, of vitamin C is less than half what it should be, scientists argue in a recent report, because medical experts insist on evaluating this natural, but critical nutrient in the same way they do pharmaceutical drugs and reach faulty conclusions as a result.

17 Jul 2012

UIC develops new tool to guide decisions about safe and effective medication use

A new tool to guide decisions about safe and effective medication use has been developed at the University of Illinois at Chicago College of Pharmacy.

17 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

Researchers identify cannabinoid-making pathway

U of S researchers have discovered the chemical pathway that Cannabis sativa uses to create bioactive compounds called cannabinoids, paving the way for the development of marijuana varieties to produce pharmaceuticals or cannabinoid-free industrial hemp.

17 Jul 2012

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

17 Jul 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012